Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its financial results for Q4 and full year 2020, highlighting significant progress despite COVID-19 challenges. The company successfully completed enrollment in its Phase 3 MAESTRO-NAFLD-1 trial with over 1,200 patients. Madrigal had cash and marketable securities of $284.1 million as of Dec 31, 2020, down from $439 million in 2019, primarily due to operational cash usage of $157.6 million. R&D expenses surged to $184.8 million, reflecting increased clinical trial activities. Key milestones for 2021 include data releases from ongoing trials.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced Dr. Stephen Harrison's presentation on Resmetirom at The Liver Meeting Digital Experience™ on November 13, 2020. The early data from Phase 3 MAESTRO trials demonstrated significant reductions in liver fat and inflammatory biomarkers. At week 16, patients showed a 53% reduction in MRI-PDFF fat levels, with 80% achieving a 30% reduction. Overall, Resmetirom shows promise for treating NASH, with no safety concerns at the 100 mg dose. Ongoing studies will further evaluate its efficacy and safety.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has completed enrollment for its MAESTRO NAFLD-1 clinical trial with over 1,200 patients, expanding from an initial goal of 700 to enhance safety data for its drug, resmetirom. The company reported third quarter 2020 financial results with cash reserves of $335.9 million, down from $439.0 million at the end of 2019, largely due to operational costs of $102.6 million. Operating expenses surged to $58.8 million for the quarter, primarily driven by increased R&D expenses of $53.3 million.
Madrigal Pharmaceuticals (NASDAQ:MDGL) recently announced significant findings from its ongoing Phase 3 MAESTRO studies on resmetirom, aimed at treating NASH patients with fibrosis stages 2-3. Data revealed high accuracy in predicting advanced NASH fibrosis using non-invasive methods. The MAESTRO-NAFLD-1 open-label arm showed robust improvements in liver fat and fibrosis after 16 weeks, with a 53% reduction in hepatic fat. The results suggest resmetirom's potential to enhance quality of life for NASH patients, demonstrated during a presentation at The Liver Meeting on November 13, 2020.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported significant findings from the ongoing Phase 3 MAESTRO-NASH study, which focuses on advanced NASH fibrosis. Using non-invasive imaging and biomarkers, the study predicts advanced fibrosis (F2-F3) with high accuracy. Data from the open-label MAESTRO-NAFLD-1 trial show a 53% reduction in liver fat at Week 16 of resmetirom treatment. The drug also demonstrated a notable decrease in atherogenic lipid levels. Dr. Stephen Harrison will present these findings at The Liver Meeting on November 13, 2020.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced that it has surpassed its enrollment target of 700 patients in the MAESTRO NAFLD-1 clinical trial for resmetirom, aimed at treating non-alcoholic steatohepatitis (NASH) with fibrosis. Following the completion of enrollment, topline data is expected by the end of next year. The trial's strong patient participation reflects the high prevalence of NASH. Secondary analyses indicated that a reduction in liver fat correlates with improvements in NASH-related histological responses. Resmetirom is designed as a β-selective thyroid hormone receptor agonist.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present secondary analyses from its Phase 2 NASH study involving MGL-3196 (resmetirom) at the Digital International Liver Congress on August 28, 2020. Dr. Rohit Loomba will discuss how MRI-PDFF reduction correlates with improvements in liver biopsy results, underscoring the drug's potential. Resmetirom is currently in Phase 3 trials, focusing on NASH patients with fibrosis stage 2-3. The results aim to demonstrate efficacy in reducing liver fat and improving cardiovascular outcomes, with a Phase 3 trial expected to enroll 900 patients.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported its Q2 2020 financial results, showing a cash balance of $384.4 million as of June 30, a decrease from $439.0 million at year-end 2019, primarily due to $54.8 million in operational costs.
Operating expenses surged to $50.3 million for Q2, up from $22.7 million in 2019. R&D expenses also rose significantly to $44.7 million, reflecting ongoing Phase 3 clinical trials. Amid challenges from the pandemic, the company is focused on completing enrollment for its MAESTRO trials and received an upgrade to the NASDAQ Global Select Market.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 2020 financial results, stating progress in its Phase 3 studies, MAESTRO-NASH and MAESTRO-NAFLD-1, despite COVID-19 challenges. The company announced a cash position of $408.5 million, down from $439.0 million at the end of 2019, primarily due to operational expenses of $30.5 million. R&D expenses surged to $33.4 million from $12.4 million year-over-year due to trial initiations. Notably, resmetirom showed over 60% reduction in liver fat and a 64% NASH resolution rate. Interest income decreased to $1.9 million.